6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge
Send us a text Fatty Liver Alliance President Mike Betel joins Roger Green to discuss his recent completion of the 3rd Annual Glucose Challenge, an event every July where Mike wears a continuous glucose monitor (CGM) device for a month, conducts food experiments, tracks glucose levels and shares all results with his LinkedIn and FattyLiver.ca friends and followers. The conversation starts with Mike sharing the history of the Glucose Challenge. Over its first three years, it has evolved ...
5 Aug 39min
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd
Send us a text 00:00:00 - Surf's Up: Episode 6.9 This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clinical trials and medical education. 00:06:12 - Global Think-Tank on SLD Roundtable, Part 3 Behavior consultant Dr. Kristina Curtis joins Jörn ...
1 Aug 1h 17min
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects
Send us a text This conversation is the fourth and final segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on...
29 Juli 16min
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed
Send us a text Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond. Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current government actions that are causing major setbacks, as well as others that have the potential to do so. Specifically, he details the challenges caused...
28 Juli 31min
6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change
Send us a text This conversation is the second segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. It focuses on the kinds of feedback most likely to produce successful behavioral interventions. The conversation begins with Jörn discussing the Liver Screen Study, a "very ambitious effort" that starts with 30,000 members of the general European population, narrows down to a subgroup with liver disease...
28 Juli 16min
6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment
Send us a text 00:00 - Surf's Up, Season 6 Episode 8 The conversation addresses three issues that are distinct, yet each is pivotal to the future of MASLD and MASH therapies. The first, from the Global Think-Tank on Steatotic Liver Disease, considers how personal and digital approaches can be combined to form the most effective strategy for patient management. In the second, Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss the new challenges in Washington ste...
26 Juli 1h 2min
S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development
Send us a text This conversation is the third segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. Louise starts the discussion by asking when a patient is metabolically and hepatically healthy instead of merely driving weight loss. She notes that basing therapy entirely on weight l...
25 Juli 14min
